AlphAIAlphAI — Financial news for AI agents
SEC EDGARJUL 202 min read$CBIO

Fairmount Funds Management LLC purchased $12.4M of CBIO (indirect holdings)

Fairmount Funds Management LLC purchased 853,450 indirectly-held shares of CRESCENT BIOPHARMA, INC. (CBIO) at $14.50 ($12.38M total) on 2026-07-16.

Original reporting
SEC EDGAR · Fairmount Funds Management LLC
Published Jul 20, 2026, 9:30 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Jul 20, 2026, 9:31 PM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
About AlphAI AI DeskScoring methodologyReport an issue
AlphAI market briefInsider activity
Primary signal
$CBIO
Neutral
medium confidence
Mentioned
$CBIO
Relevance
8/10
AlphAI data visualization · based on SEC EDGAR
Decision brief

The 30-second read

$CBIONeutralLow
01

Why it matters

The newest concrete fact is the disclosed open-market purchase size, price, and post-transaction share count, which can modestly influence sentiment but does not provide new operational or financial information about CBIO.

02

Market read

Traders may note the sizable disclosed buy, but the lack of company-specific catalysts keeps the expected impact modest.

03

What to watch

No 10b5-1 plan is stated, but the filing does not clarify intent, horizon, or whether other insiders/funds are acting similarly; without follow-on disclosures, signal strength is limited.

Relevance 8/10Novelty 5/10Timing: Filed 2026-07-20, covering a purchase executed 2026-07-16.

Background

The article is an SEC Form 4 insider transaction disclosure for Crescent Biopharma, Inc. (CBIO), reported by Fairmount Funds Management LLC as an indirect holding.

Company-level read

Ticker impact

$CBIONeutralMedium confidence
Context

Fairmount Funds Management LLC filed a Form 4 showing an open-market purchase of 853,450 CBIO shares for about $12.38M on 2026-07-16.

Expected impact

Likely limited immediate price impact; any effect would be sentiment-driven and should fade unless followed by additional disclosures or fundamentals.

Evidence & confidence

The filing is a primary SEC Form 4 disclosure with transaction size and price, but it is an indirect holding by a fund/owner and lacks accompanying company-specific catalysts (no guidance, trial, or deal).

Market effects

Sector

Minimal, as the disclosure is company-specific and does not include sector-wide regulatory or clinical updates.

Regional

None indicated.

Global

None indicated.

Counterpoint

What could challenge this read

A large purchase by an indirect holder can reflect portfolio rebalancing or mandate changes rather than a new bullish thesis on Crescent Biopharma’s near-term prospects.

Key entities

  • issuer
    Crescent Biopharma, Inc.

    Subject of the Form 4 disclosure, with the reported purchase of 853,450 shares at $14.50 on 2026-07-16.

  • reporting_party
    Fairmount Funds Management LLC

    Reported the transaction as an indirect holding; roles listed as Director and 10% Owner.

Read at source← All news

Full insider trading history

This story covers one filing. See everything behind it: every insider buy and sell on record, 10b5-1 plans, late filings, and which officers and directors are trading.

CBIO insider trading history →

Related articles

OCT 19
$CBIOMed

H.C. Wainwright reiterates Crescent Biopharma stock rating at buy

H.C. Wainwright reiterated a Buy rating and $36.00 price target on Crescent Biopharma (CBIO), citing progress in mid-stage clinical trials for its CR-001 drug. The stock trades at $11.84, with potential upside of over 200%. Crescent announced completion of dose escalation in its ASCEND trial and enrollment of over 125 patients. The company aims to dose over 2,000 patients by mid-2027 and start Phase 3 trials in early 2028.

investing.com2 min
OCT 16
$CBIOHighAI 8/10

Stifel reiterates Crescent Biopharma stock rating on pipeline progress

Stifel maintained a Buy rating and $28.00 price target for Crescent Biopharma (CBIO) after its pipeline update, noting progress in trials and patient dosing. The stock, trading at $12.48, has dropped 16% in a week. Crescent recently raised $143.7M via a public offering, with H.C. Wainwright upgrading its rating to Buy with a $36.00 target. The company's enterprise value is below $500M, and it expects to dose over 2,000 patients by mid-2027.

investing.com2 min
OCT 15
$CBIOMed

Crescent Biopharma advances CR-001 combos, clears IND for CR-002 and sets mid‑2027 data timelines

Crescent Biopharma (CBIO) announced enrollment in CR-001 chemo combination cohorts and IND allowance for CR-002, with initial data expected in 2027. The company completed CR-001 monotherapy dose escalation and expects initial monotherapy data from over 125 patients and ORR in up to 12 1L NSCLC patients by Q1 2027. The FDA allowed IND for CR-002, with a global Phase 1/2 APOLLO trial to start Q4 2026 and initial data anticipated in H2 2027.

tradingview.com1 min
OCT 15
$CBIOMed

Crescent Biopharma, Inc. issued a press release announcing clinical pipeline updates, including (i) enrolling patients in cohorts combining CR-001, a PD-1 x…

CRESCENT BIOPHARMA, INC. (CBIO) filed an SEC Form 8-K — Other Events. Item 8.01 Other Events. On October 15, 2026, Crescent Biopharma, Inc. (“Crescent” or the “Company”) issued a press release announcing clinical pipeline updates, including (i) enrolling patients in cohorts combining CR-001, a PD-1 x VEGF bispecific antibody, plus standard of care

SEC EDGAR 8-K4 min
OCT 6
$CBIOHigh

Crescent Biopharma stock rating upgraded to buy at H.C. Wainwright

H.C. Wainwright upgraded Crescent Biopharma (CBIO) to Buy with a $36.00 price target, citing potential catalysts in 2027. The stock is currently trading at $13.94. The firm highlighted the company's antibody-drug conjugate pipeline and recent public offering raising $143.7 million. CBIO's balance sheet shows more cash than debt, a strength for a clinical-stage biotech.

investing.com2 min